The precise recognition

detection

and analysis of protein biomarkers are essential for disease diagnosis and life sciences research. Antibody probes

known for their high specificity and stability

are crucial to biomolecular sensing assays. Traditionally

antibody development has relied on “carbon-based” approaches using animal immune systems. However

we are currently undergoing a transformative shift toward “silicon-based” methods driven by artificial intelligence (AI). Conv

entional techniques

such as animal-based antibody production and phage display-based directed evolution

have long been challenged by low efficiency and limited control over epitope specificity and binding affinity. Recent AI advances

including

de

novo

protein design and deep learning-driven protein binding protein (PBP) generation

are revolutionizing antibody development. These innovations enable the rapid creation of protein-based biosensing probes (

e.g.

antibodies and nanobodies) with enhanced specificity and affinity

along with accurate predictions of epitopes and structural features. By overcoming limitations with traditional methods

AI-driven technologies offer unprecedented control over the design and performance of antibody probes. Furthermore

“silicon-based evaluation” plays a key role in PBP generation

allowing for quantitative assessment of binding affinity

stability

and robustness. AI-designed biosensing probes offer potentials for capturing a broader spectrum of biomolecular information

which may be able to detect variations in sequence and conformation

post-translational modifications

abnormal polymerization

and shifts in biological activity. In certain diseases

the abnormal dissociation of multimeric proteins can reveal previously concealed antigenic epitopes

creating disease-specific targets

which can be better addressed with AI-designed probes for more accurate and nuanced insights. Moreover

modern high-performance biomolecular sensing technologies

such as bead-based chemiluminescent immunoassays (CLIA)

digital immunoassay

microfluidic immunoassay

and single molecule binding kinetics assays

require highly diverse antibody specificity and affinity

and AI-based protein design tools can meet these divergent needs

enabling the integration of AI-engineered biosensing probes with next-generation sensors. This integration not only enhances detection sensitivity

but also expands the scope of molecular information that can be ana

lyzed. Such a paradigm shift represents a new era in biomolecular sensing

and offers exciting prospects for precision medicine and synthetic biology.

2